....and I've been doing some analysis of Celgene's reported net sales for Pomalyst. Based upon my calculations, I believe they are significantly overstating US sales figures for this product.
Based on the size of the treatable population within the relapsed/refractory multiple myeloma market in the US, current Pomalyst market share, and current cost of Pomalyst therapy, I simply cannot generate revenue close to what Celgene is reporting.
In my opinion, the bottom line is that AIG needs to reinvest its float in more accretive areas than treasuries yielding 3%.
They should be looking to move into more lucrative specialty lines of insurance, aquire smaller companies, and invest in higher-yielding instruments (many EU, Chinese, Russian corp bonds are beaten down unfairly at the current time). There has to be a booming market for insurance against cyber attacks, etc.
suggests to me that people expect Yellen will stay the course of expected interest rate hikes in September.
Interest rates hikes are very helpful to insurance companies, especially those who invest in as much government paper as AIG does. We have become so accustom to low interest rates, that it is hard to visualize a normalized environment.
The Apple iPhone has never existed in an economy with an interest rate hike. Think about that for a second.